Company profile
CEL-SCI Corporation
AMEX: CVM · Healthcare · Biotechnology
PublicHQ Vienna, VACIK 0000725363Reports USD
#980 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
32DFH 25DQ 19GM 61SS 65
v0.1 · 65/100 weight · provisional
↑ listing tenure, revenue growth (YoY) · ↓ operating margin, net margin
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$25.4M
Employees
43
as of 2026-08-23
Market cap
$9.8M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$264.0k$264.0k2014
Net income-$25.4M-$25.4M2025
Operating income-$24.8M-$24.8M2025
Total assets$28.2M$28.2M2025
Liabilities$12.2M$12.2M2025
Equity$16.0M$16.0M2025
Revenue trend
FY2013 – FY2014 · USD
FY13
FY13
FY13
FY13
FY14
FY14
FY14
FY14
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is CEL-SCI Corporation’s revenue?
CEL-SCI Corporation booked $264.0k in FY2014 revenue, growing 1559% year over year — faster than 97% of Healthcare companies we track, at a -9624.2% net margin.
Peers · Healthcare
Aion Therapeutic Inc.——Abattis Bioceuticals Corp.——Entia Biosciences, Inc.——Nutra Pharma Corp.30DNewCardio, Inc.——Savara Inc.50DKey facts
CEOGeert R. Kersten
SectorHealthcare
IndustryBiotechnology
HeadquartersVienna, VA
ExchangeAMEX: CVM
Employees43
IPO date1983-12-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.